Early research conducted at the University of Birmingham, UK, shows that the novel ATM blocker AZD1390 can promote regeneration of damaged nerve cells, potentially restoring sensory and motor function after a spinal injury.
The research, published in the journal Clinical and Translational Medicine, used cell and animal models to demonstrate the impact of the oral therapy on the body’s response to DNA damage.
The brain-penetrating candidate is being evaluated under AstraZeneca’s (LSE: AZN) Open Innovations Program, which shares compounds, tools, technologies and expertise with the scientific community.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze